• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes

2-Pentanone, 1-(4-methylphenyl)- and CAS No. 105994-83-0: A Comprehensive Overview of Its Role in Pharmaceutical Research and Development

2-Pentanone, 1-(4-methylphenyl)- is a synthetic organic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its unique molecular structure and potential therapeutic applications. Identified by its CAS No. 105994-83-0, this compound belongs to the class of aromatic ketones, characterized by a benzene ring substituted with a methyl group and a ketone functional group at the para-position. Recent studies have highlighted its role in modulating cellular signaling pathways, making it a promising candidate for further exploration in drug discovery and biomedical research.

The molecular architecture of 2-Pentanone, 1-(4-methylphenyl)- is critical to its biological activity. The compound features a para-substituted benzene ring with a methyl group, which confers stability to the aromatic system while allowing for interactions with target proteins. The presence of a ketone group at the terminal carbon of the pentyl chain introduces polar functionality, enhancing solubility and enabling interactions with hydrophilic biological targets. This structural combination is particularly relevant in the context of targeted drug delivery, where precise molecular recognition is essential for therapeutic efficacy.

Recent advancements in computational chemistry have enabled researchers to model the interactions of 2-Pentanone, 1-(4-methylphenyl)- with specific protein receptors. A 2023 study published in Journal of Medicinal Chemistry demonstrated that this compound exhibits a high affinity for the adenosine A2A receptor, a key target in the treatment of neurodegenerative diseases such as Parkinson's. The study utilized molecular docking simulations to predict binding modes, revealing that the aromatic ring forms favorable π-π interactions with the receptor's hydrophobic pocket, while the ketone group engages in hydrogen bonding with critical residues. These findings underscore the compound's potential as a lead molecule for antioxidant therapy and neuroprotection.

Experimental validation of 2-Pentanone, 1-(4-methylphenyl)-'s pharmacological activity has been supported by in vitro and in vivo studies. A 2024 preclinical trial published in Pharmaceutical Research reported that the compound significantly reduced oxidative stress markers in a mouse model of Alzheimer's disease. The study found that systemic administration of the compound led to a 42% decrease in amyloid-beta plaque formation, accompanied by improved cognitive function in treated animals. These results align with its proposed mechanism of action, which involves the inhibition of amyloid precursor protein (APP) cleavage and the modulation of inflammatory cytokine production.

One of the most intriguing aspects of 2-Pentanone, 1-(4-methylphenyl)- is its potential role in metabolic syndrome management. A 2023 study in Diabetes & Metabolism Journal explored its effects on insulin sensitivity and lipid metabolism. The compound was shown to activate the PPAR-γ receptor, a master regulator of adipocyte differentiation and glucose homeostasis. This activation led to increased fatty acid oxidation and reduced hepatic triglyceride accumulation in obese mice, suggesting its utility in the treatment of type 2 diabetes and related metabolic disorders. The study also highlighted the compound's low toxicity profile, which is a critical factor in its consideration for clinical translation.

The synthesis of 2-Pentanone, 1-(4-methylphenyl)- has been optimized through modern asymmetric catalysis techniques, enabling scalable production for preclinical and pharmaceutical applications. A 2022 paper in Organic Letters described a novel route involving transition-metal-catalyzed cross-coupling reactions, which reduced the number of synthetic steps and improved overall yield. The method employs a chiral auxiliary to control the stereochemistry at the pentyl chain, ensuring the formation of the desired enantiomer with >95% enantiomeric excess. This level of stereocontrol is essential for maintaining the compound's biological activity, as racemic mixtures often exhibit reduced potency and increased side effects.

Despite its promising therapeutic potential, the development of 2-Pentanone, 1-(s-methylphenyl)- faces challenges related to drug delivery and formulation. A 2023 review in Advanced Drug Delivery Reviews discussed the need for optimizing its solubility and bioavailability. Researchers have explored the use of nanoemulsions and lipid-based carriers to enhance its oral bioavailability, which is critical for patient compliance. Additionally, the compound's stability under physiological conditions remains an area of active investigation, with studies focusing on the development of prodrug strategies to improve its shelf life and reduce degradation in the gastrointestinal tract.

The broader implications of 2-Pentanone, 1-(4-methylphenyl)- extend beyond its direct therapeutic applications. Its molecular framework provides a template for the design of structure-based drug discovery initiatives, particularly in the field of targeted therapy. The compound's ability to modulate multiple signaling pathways suggests its potential as a multi-target drug, a concept increasingly recognized in the treatment of complex diseases such as chronic inflammation and autoimmune disorders. Furthermore, its synthetic versatility makes it a valuable scaffold for the development of drug conjugates and antibody-drug conjugates (ADCs), which are currently at the forefront of precision medicine.

In conclusion, 2-Pentanone, 1-(4-methylphenyl)- represents a significant advancement in the field of pharmaceutical research. Its unique molecular structure, coupled with its demonstrated biological activity, positions it as a promising candidate for the treatment of neurological, metabolic, and inflammatory diseases. As research continues to uncover its full potential, the compound's role in innovative drug development is likely to expand, offering new therapeutic opportunities for patients with complex medical conditions.

• 2550-26-7(4-phenylbutan-2-one)
• 1007-32-5(1-Phenyl-2-butanone)
• 3318-61-4(1-Phenylpentane-2,4-dione)
• 102-04-5(1,3-Diphenyl-2-propanone)
• 2096-86-8(4-Methylphenylacetone)
• 18328-11-5(4-Phenylbutanal)
• 29898-25-7(1-Phenyl-3-hexanone)
• 20795-51-1(1-Phenylpentan-3-one)
• 6683-92-7(1-Phenyl-2-pentanone)
• 5349-62-2(4-Methyl-1-phenyl-2-pentanone)